Evidence map›Paper›PMID 32051557›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment.

Sanjay S Patel, Mikel Lipschitz, Geraldine S Pinkus, Jason L Weirather, Olga Pozdnyakova, Emily F Mason, Giorgio Inghirami, Robert P Hasserjian, Scott J Rodig, Olga K Weinberg

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Artificial Intelligence in Bone Marrow Histological Diagnostics: Potential Applications and Challenges.Pathobiology : journal of immunopathology, molecular and cellular biology · 2024
    Review
  6. Article
  7. Article
  8. NPM1 Biology in Myeloid Neoplasia.Current hematologic malignancy reports · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Sanjay S PatelDivision of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Mikel LipschitzCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Geraldine S PinkusDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Jason L WeiratherCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0556-0616
Olga PozdnyakovaDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Emily F MasonDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Giorgio InghiramiDivision of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0001-5566-0864
Robert P HasserjianDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Scott J RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Olga K WeinbergDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA. olga.weinberg@childrens.harvard.edu.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USCornell University · USMassachusetts General Hospital · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ancillary testing during the initial workup of acute myeloid leukemia (AML) is largely performed using aspirated materials. We utilized multiplex immunofluorescence (MIF) imaging with digital image analysis to perform an in situ analysis of the microenvironment in NPM1-mutated AML using diagnostic bone marrow biopsy tissues (N = 17) and correlated these findings with diagnostic next-generation sequencing (NGS, N = 17), flow cytometry (FC, N = 14), and first remission (CR1) NPM1-specific molecular MRD (n = 16) data. The total CD3-positive T-cell percentages correlated positively between FC and MIF (r = 0.53, p = 0.05), but were significantly lower by MIF (1.62% vs. 3.4%, p = 0.009). The percentage of mutant NPM1-positive (NPM1c+) cells ranged from 9.7 to 90.8% (median 45.4%) and did not correlate with the NPM1 mutant allele fraction by NGS (p > 0.05). The percentage of CD34+/NPM1c+ cells ranged from 0 to 1.8% (median 0.07%). The percentage of NPM1c+ cells correlated inversely (34% vs. 62%, p = 0.03), while the percentages of CD3-/NPM1c- cells (64% vs. 35%, p = 0.03), and specifically CD3-/CD4-/NPM1c- cells (26% vs. 13%, p = 0.04), correlated positively with subsequent MRD. Discordances between MIF and FC/NGS data suggest that aspirate materials are likely an imperfect reflection of the core biopsy tissue. Furthermore, increased numbers of NPM1 wild-type cells within the microenvironment at diagnosis correlate with the subsequent presence of MRD.

Indexed as

Tumor MicroenvironmentAdultAgedBone MarrowFemaleFluorescent Antibody TechniqueHumansImage Interpretation, Computer-AssistedLeukemia, Myeloid, AcuteMaleMiddle AgedNuclear ProteinsNucleophosminPrognosisNPM1 protein, humanNuclear ProteinsNucleophosmin

Identifiers

PMID32051557
OpenAlexW3006180246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.